EYPT - EyePoint, Inc. So'nggi Yangiliklar | Finranks

EyePoint: Phase 3 Design Creates A More Valuable Durability Story

EyePoint: Phase 3 Design Creates A More Valuable Durability Story

EyePoint Pharmaceuticals approaches a binary valuation inflection with pivotal Phase III LUGANO data for DURAVYU in wet AMD due August 2026. EYPT's clinical program emphasizes repeat six-month dosing, broad patient inclusion, and direct comparison to on-label aflibercept, supporting commercial relevance. Ownership of manufacturing infrastructure and Durasert E platform applicability to both wet AMD and DME strengthens EYPT's strategic positioning.

EyePoint (EYPT) Reports Q2 Loss, Beats Revenue Estimates

EyePoint (EYPT) Reports Q2 Loss, Beats Revenue Estimates

EyePoint (EYPT) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to a loss of $0.85 per share a year ago.

EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments

EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments

– Topline data from LUGANO pivotal Phase 3 wet AMD clinical trial expected in August 2026 –– – Topline data from LUCIA pivotal Phase 3 wet AMD clinical trial anticipated in Q4 2026 –– – Pivotal Phase 3 DME clinical trials, COMO and CAPRI, fully enrolled over 480 patients in 5 months; topline data expected in Q4 2027 –– – $180 million of cash and investments as of June 30, 2026, with runway into Q4 2027 –– WATERTOWN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the second quarter ended June 30, 2026, and highlighted recent corporate developments.

Videolar

No Data

There is no data to display

Press-relizlar

EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments

EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments

– Topline data from LUGANO pivotal Phase 3 wet AMD clinical trial expected in August 2026 –– – Topline data from LUCIA pivotal Phase 3 wet AMD clinical trial anticipated in Q4 2026 –– – Pivotal Phase 3 DME clinical trials, COMO and CAPRI, fully enrolled over 480 patients in 5 months; topline data expected in Q4 2027 –– – $180 million of cash and investments as of June 30, 2026, with runway into Q4 2027 –– WATERTOWN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the second quarter ended June 30, 2026, and highlighted recent corporate developments.